Literature DB >> 6491298

Efficient selection of human tumor growth-inhibiting monoclonal antibodies.

D Herlyn, M Herlyn, A H Ross, C Ernst, B Atkinson, H Koprowski.   

Abstract

A method is described for selection early after fusion for hybridomas that secrete IgG2a monoclonal antibodies (MAbs) with binding specificity for antigens on the human tumor cells used to immunize mice. By combining this preselection method with antibody-dependent macrophage-mediated cytotoxicity assays, it was possible to select those MAbs mediating a tumoricidal effect against tumor cells in culture and inhibiting the growth of tumor xenografts in nude mice. Two such MAbs, GA733 and CO441, inhibited the growth of colorectal carcinoma cells, and one of them (GA733) was effective even when administered 6 days after implantation of tumor cells. These results suggest the potential usefulness of the 2 MAbs in immunodiagnosis and immunotherapy of human tumors.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6491298     DOI: 10.1016/0022-1759(84)90041-3

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  28 in total

Review 1.  Recombinant antibodies for the diagnosis and treatment of cancer.

Authors:  Jürgen Krauss
Journal:  Mol Biotechnol       Date:  2003-09       Impact factor: 2.695

Review 2.  EpCAM and its potential role in tumor-initiating cells.

Authors:  Sannia Imrich; Matthias Hachmeister; Olivier Gires
Journal:  Cell Adh Migr       Date:  2012 Jan-Feb       Impact factor: 3.405

3.  Tumor-associated antigen expression and growth requirements predict tumorigenesis in squamous cell carcinoma.

Authors:  E R Salter; D Tichansky; E E Furth; A M Herlyn
Journal:  In Vitro Cell Dev Biol Anim       Date:  2001-09       Impact factor: 2.416

4.  Cellular image analysis and imaging by flow cytometry.

Authors:  David A Basiji; William E Ortyn; Luchuan Liang; Vidya Venkatachalam; Philip Morrissey
Journal:  Clin Lab Med       Date:  2007-09       Impact factor: 1.935

5.  Normal colon of Sprague-Dawley rats. An immunohistochemical study.

Authors:  J D Shetye; C A Rubio; H T Mellstedt
Journal:  Anat Embryol (Berl)       Date:  1992

6.  Molecular cloning of cDNA for the human tumor-associated antigen CO-029 and identification of related transmembrane antigens.

Authors:  S Szala; Y Kasai; Z Steplewski; U Rodeck; H Koprowski; A J Linnenbach
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

7.  Nucleophosmin is recognized by a cytotoxic T cell line derived from a rectal carcinoma patient.

Authors:  Rolf K Swoboda; Rajasekharan Somasundaram; Laura Caputo; Klara Berencsi; Paul von Franzke; Douglas D Taylor; Francesco M Marincola; Neal J Meropol; Elin Sigurdson; Eric Miller; Dorothee Herlyn
Journal:  Int J Cancer       Date:  2010-09-01       Impact factor: 7.396

8.  The expression of colorectal carcinoma-associated antigens in the normal colonic mucosa. An immunohistochemical analysis of regional distribution.

Authors:  B C Wolf; R R Salem; H F Sears; D A Horst; P T Lavin; M Herlyn; S H Itzkowitz; J Schlom; G D Steele
Journal:  Am J Pathol       Date:  1989-07       Impact factor: 4.307

9.  Immunohistochemical monitoring of metastatic colorectal carcinoma in patients treated with monoclonal antibodies (MAb 17-1A).

Authors:  J Shetye; J E Frödin; B Christensson; C Grant; B Jacobsson; S Sundelius; M Sylvén; P Biberfeld; H Mellstedt
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

10.  HER-2 gene amplification can be acquired as breast cancer progresses.

Authors:  Songdong Meng; Debasish Tripathy; Sanjay Shete; Raheela Ashfaq; Barbara Haley; Steve Perkins; Peter Beitsch; Amanullah Khan; David Euhus; Cynthia Osborne; Eugene Frenkel; Susan Hoover; Marilyn Leitch; Edward Clifford; Ellen Vitetta; Larry Morrison; Dorothee Herlyn; Leon W M M Terstappen; Timothy Fleming; Tanja Fehm; Thomas Tucker; Nancy Lane; Jianqiang Wang; Jonathan Uhr
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-11       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.